New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
07:31 EDTXLRN, GERN, ARGS, THLD, MDCO, EGRX, ANAC, SGMO, INSY, DSCOPiper Jaffray to hold a symposium
Catalyst Symposium to be held in Boston on July 8.
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
07:20 EDTINSYInsys Therapeutics cannabidiol receives fast track designation From FDA
Subscribe for More Information
07:14 EDTSGMOSangamo's XFP Thereapeutic HIV candidate shows positive trial results
Subscribe for More Information
February 25, 2015
10:01 EDTARGSOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:33 EDTARGSArgos Therapeutics initiated with a Buy at MLV & Co.
Subscribe for More Information
February 24, 2015
08:33 EDTARGSArgos Therapeutics hires Joan Winterbottom as Chief Human Resources Officer
Argos Therapeutics (ARGS) announced that Joan Winterbottom will join the company as chief human resources officer. Winterbottom most recently served as senior vice president of human resources at Amicus Therapeutics (FOLD).
07:07 EDTINSYInsys Therapeutics in-licenses novel mast cell therapy for chronic pelvic pain
Subscribe for More Information
February 23, 2015
10:26 EDTEGRXEagle Pharmaceuticals granted seven years of market exclusivity to Ryanodex
Subscribe for More Information
07:22 EDTXLRNSunTrust to hold a conference
2015 Biotechnology and Pharmaceutical 1:1 Orphan Drug Day is being held in New York on February 23.
February 19, 2015
18:25 EDTSGMOPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
February 18, 2015
08:54 EDTMDCOThe Medicines Co. anticipates potential partnership talks
Subscribe for More Information
08:52 EDTMDCOThe Medicines Co. anticipates four U.S. FDA approvals in 2015
08:41 EDTMDCOThe Medicines Co. says not giving financial guidance due to Hospira suit
Subscribe for More Information
07:45 EDTEGRXEagle Pharmaceuticals price target raised to $37 from $30 at Cantor
Subscribe for More Information
07:13 EDTEGRXEagle Pharmaceuticals target raised to $43 from $25 at William Blair
William Blair raised its price target for Eagle Pharmaceuticals (EGRX) to $43 saying the company's agreement with Teva (TEVA) removes a major overhang on the stock. William Blair says the deal is a significant positive for Eagle since it removes litigation risk and moves the company immediately into profitability. It keeps an Outperform rating on the stock.
07:01 EDTMDCOThe Medicines Co. reports Q4 adjusted EPS 20c, consensus (82c)
Subscribe for More Information
February 17, 2015
16:07 EDTEGRXEagle Pharmaceuticals reports Q4 EPS (39c), consensus (49c)
Subscribe for More Information
08:39 EDTEGRXTeva deal small but important, says BMO Capital
Subscribe for More Information
07:04 EDTEGRXTeva, Eagle enter license agreement for EP-3102
Teva Pharmaceutical Industries (TEVA) and Eagle Pharmaceuticals (EGRX) announce that the companies have entered into an exclusive license agreement for EP-3102, Eagle’s bendamustine hydrochloride rapid infusion product for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Teva will be responsible for all U.S. commercial activities for the product including promotion and distribution. Eagle has responsibility for obtaining all regulatory approvals, conducting post-approval clinical studies, if required, and initially supplying drug product to Teva. As part of the agreement, Teva will waive its orphan drug exclusivities for NHL and CLL with respect to EP-3102, which should allow the product to come to market more quickly. Under the terms of the exclusive license agreement, Eagle will receive an upfront cash payment of $30M and is eligible to receive up to $90M in additional milestone payments. In addition, Eagle will receive double-digit royalties on net sales of the product, assuming FDA approval. The companies will also settle the pending patent infringement action between them.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use